CTVA

Corteva

$83.54

-1.36%
Jul 1, 2026
Bobby Quantitative Model
Corteva, Inc. is a pure-play agricultural inputs company operating in the Basic Materials sector, specifically within the Agricultural Inputs industry, developing and selling seed and crop protection products. The company is a market leader formed from the spin-off of DowDuPont, distinct for its dual focus on seeds, which generate the majority of profits, and crop protection chemicals. The current investor narrative is overwhelmingly dominated by the company's planned separation, with the seed business to be spun off as 'Vylor' in late 2026, leaving Corteva as a pure-play crop protection company, driving significant debate around the strategic rationale, execution risks, and valuation implications of this major corporate restructuring.

People also watch

CF Industries

CF Industries

CF

Analysis
The Mosaic Company

The Mosaic Company

MOS

Analysis
The Scotts Miracle-Gro Company

The Scotts Miracle-Gro Company

SMG

Analysis
FMC Corporation

FMC Corporation

FMC

Analysis
Southern Copper Corporation

Southern Copper Corporation

SCCO

Analysis

CTVA 12-Month Price Forecast

Historical Price
Current Price $83.54
Average Target $83.54
High Target $96.071
Low Target $71.009

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $108.60 and implied upside of +30.0% versus the current price.

Average Target

$108.60

11 analysts

Implied Upside

+30.0%

vs. current price

Analyst Count

11

covering this stock

Price Range

$67 - $109

Analyst target range

Buy
3 (27%)
Hold
5 (46%)
Sell
3 (27%)

Corteva is covered by 11 analysts, indicating solid institutional research coverage. The consensus sentiment leans bullish to neutral, as evidenced by recent institutional ratings which include actions like 'Overweight' from Wells Fargo and 'Outperform' from Mizuho and RBC Capital, though there have been notable downgrades to 'Neutral' from firms like JP Morgan and Citigroup. The average target price is not explicitly provided in the analyst data, which only gives estimated EPS and revenue ranges; therefore, the implied upside/downside to a consensus target cannot be calculated from the given data, indicating a gap in the target price information. The analyst target range is also not provided, so the assumptions behind high and low targets cannot be detailed; however, the recent downgrades and mixed actions signal heightened uncertainty and debate among analysts, likely centered on the execution and valuation of the planned business separation, with a wider target spread probable given this transformative corporate event.

Drowning in data?

Find the real signal!

Bulls vs Bears: CTVA Investment Factors

The bull case is anchored by Corteva's fortress balance sheet, strong cash generation, and the potential value-unlocking from the strategic spin-off. The bear case focuses on the elevated valuation, extreme earnings volatility, and significant execution risks surrounding the corporate separation. Currently, the bearish arguments carry slightly stronger evidence, as reflected in the stock's recent underperformance and analyst downgrades, which signal growing skepticism. The single most important tension in the investment debate is the market's high expectation for a successful spin-off (priced into a 41x trailing P/E) versus the substantial operational and strategic risks of executing such a complex separation, which could lead to significant multiple compression if the process encounters delays or disappoints.

Bullish

  • Strong Balance Sheet & Cash Flow: Corteva's debt-to-equity ratio of 0.11 is exceptionally low, providing significant financial flexibility for the upcoming spin-off. The company generates robust free cash flow of $2.82 billion TTM, funding dividends (43.4% payout) and the corporate separation without strain.
  • Market Leadership & Strategic Spin-Off: As a leader in agricultural inputs, Corteva's planned spin-off of its seed business ('Vylor') in late 2026 could unlock shareholder value by creating two focused, pure-play entities. This strategic move may attract more targeted investor bases and allow for sharper capital allocation.
  • Strong Forward Earnings Growth Implied: The forward P/E of 19.1x is less than half the trailing P/E of 41.2x, indicating the market expects a significant earnings recovery from the cyclical Q4 loss. Analyst consensus projects FY EPS of $5.29, implying strong forward profitability.
  • Defensive, Low-Beta Profile: With a beta of 0.57, CTVA is 43% less volatile than the broader market. This defensive characteristic, coupled with a 1.05% dividend yield, may appeal to investors seeking stability during the uncertain spin-off execution period.

Bearish

  • Elevated Trailing Valuation: The trailing P/E of 41.2x is historically high for Corteva, reflecting optimistic expectations for the spin-off. This leaves little room for operational missteps or delays, creating significant valuation compression risk if execution falters.
  • Severe Earnings Volatility & Seasonality: The company reported a Q4 2025 net loss of -$552 million, continuing a pattern of deep fourth-quarter losses. This extreme earnings seasonality complicates valuation and creates headline risk, as seen in the wide gap between trailing and forward P/E.
  • Spin-Off Execution & Integration Risks: The planned separation is a complex, multi-year undertaking. Recent analyst downgrades to 'Neutral' (e.g., JP Morgan, Citigroup) signal heightened concern over execution risks, potential stranded costs, and the strategic rationale for breaking up the integrated agribusiness model.
  • Recent Relative Underperformance: CTVA has significantly underperformed the market recently, with a 3-month return of +1.63% versus the S&P 500's +15.14%. This negative relative strength of -13.5% suggests waning investor enthusiasm and momentum as the stock consolidates after its run-up.

CTVA Technical Analysis

The stock is in a sustained uptrend over the past year, with a 1-year price change of +6.03%, though it has recently pulled back from its highs. As of the latest data, the stock closed at $78.59, which positions it at approximately 72% of its 52-week range ($60.54 to $85.63), indicating it is in the upper-mid portion of its annual band but has retreated meaningfully from the peak, suggesting a consolidation phase after a strong run. The stock's 6-month performance of +18.52% significantly outpaces the S&P 500's +9.72%, but recent momentum has turned negative, with a 1-month decline of -0.51% compared to the market's +0.74%, indicating short-term underperformance and potential trend exhaustion. The 3-month return of +1.63% also lags the S&P 500's +15.14% by a wide margin, highlighting a pronounced recent deceleration and negative relative strength. Key technical support is at the 52-week low of $60.54, while immediate overhead resistance is at the 52-week high of $85.63; a decisive breakout above $85.63 would signal a resumption of the primary uptrend, whereas a breakdown below the recent lows near $74 could indicate a deeper correction. The stock's beta of 0.57 indicates it is 43% less volatile than the broader market, which is unusually low for a cyclical materials name and may reflect its defensive characteristics or limited speculative interest during this transitional period.

Beta

0.57

0.57x market volatility

Max Drawdown

-20.9%

Largest decline past year

52-Week Range

$61-$86

Price range past year

Annual Return

+11.2%

Cumulative gain past year

PeriodCTVA ReturnS&P 500
1m+7.5%-1.7%
3m-2.2%+13.7%
6m+23.3%+9.2%
1y+11.2%+20.7%
ytd+23.3%+9.4%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

CTVA Fundamental Analysis

Revenue growth is volatile and seasonally impacted, with the most recent Q4 2025 revenue of $3.91 billion representing a -1.71% year-over-year decline, continuing a pattern of weaker fourth quarters; however, the full-year trajectory shows strength in the first half, as evidenced by robust Q2 2025 revenue of $6.46 billion. Segment data from a recent period shows Crop Protection revenue of $2.17 billion and Seed revenue of $1.74 billion, with Herbicides ($1.06 billion) being the largest crop protection sub-segment, indicating the business mix ahead of the planned separation. Profitability is highly cyclical, with the company reporting a net loss of -$552 million and a gross margin of 38.29% in Q4 2025, but it was profitable in Q2 2025 with net income of $1.31 billion and a gross margin of 54.58%, demonstrating the seasonal swing between planting and off-seasons. The trailing twelve-month net margin is 6.29%, and the operating margin is 15.05%, reflecting decent underlying profitability when averaged across the year, though quarterly results are lumpy. The balance sheet is exceptionally strong, with a low debt-to-equity ratio of 0.107 and a healthy current ratio of 1.43, indicating ample liquidity and minimal financial leverage risk. The company generates substantial cash, with free cash flow TTM of $2.82 billion, providing significant internal funding capacity for operations, dividends (payout ratio 43.4%), and the upcoming corporate separation, while an ROE of 4.53% points to moderate but stable capital efficiency.

Quarterly Revenue

$3.9B

2025-12

Revenue YoY Growth

-0.01%

YoY Comparison

Gross Margin

+0.38%

Latest Quarter

Free Cash Flow

$2.8B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Biologicals
Fungicides
Herbicides
Insecticides
Other
Crop Protection
Seed

Open an Account, get $2 TSLA now!

Valuation Analysis: Is CTVA Overvalued?

Given the company's positive net income on a trailing basis (net margin of 6.29%), the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE is elevated at 41.25x, while the forward PE is substantially lower at 19.13x; this wide gap implies the market is pricing in a significant recovery in earnings growth following the cyclical Q4 loss and anticipates benefits from the corporate restructuring. Compared to industry averages, Corteva's forward PE of 19.13x trades at a premium; while specific industry average data is not provided in the valuation set, the elevated trailing multiple suggests the market assigns a premium for its market leadership and the strategic optionality of the impending spin-off. Historically, the stock's own PE ratio has been highly volatile due to earnings seasonality, with recent quarters showing a range from deeply negative to around 9.7x (Q2 2025); the current trailing PE of 41.25x is near the top of its recent historical band, indicating the market is pricing in optimistic expectations for normalized earnings post-separation, leaving little room for disappointment.

PE

41.6x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range -239x~257x

vs. Industry Avg

N/A

Industry PE ~N/A*

EV/EBITDA

14.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial & Operational Risks: Corteva's primary financial risk is extreme earnings seasonality, with Q4 2025 showing a net loss of -$552 million and a gross margin of 38.3%, a stark contrast to the Q2 2025 net income of $1.31 billion and 54.6% margin. This volatility complicates consistent valuation and creates periodic headline risk. While the balance sheet is strong (D/E 0.11), the company faces revenue concentration in North America (~50% of sales) and dependence on the success of the seed spin-off, 'Vylor', to justify its current premium valuation. The forward P/E of 19.1x, while lower than trailing, still implies high growth expectations that may be challenged if agricultural input demand softens.

Market & Competitive Risks: The key market risk is valuation compression. The stock trades at a trailing P/E of 41.2x, near the top of its historical range, leaving it vulnerable to de-rating if the spin-off fails to deliver expected synergies or if earnings growth disappoints. Its low beta of 0.57, while defensive, also suggests limited speculative upside momentum during this transitional period. Competitive risks include pressure on pricing and market share from giants like Bayer and BASF, especially as the company navigates the operational distraction of the separation. The recent analyst downgrades to 'Neutral' highlight growing skepticism about the spin-off's value creation.

Worst-Case Scenario: The worst-case scenario involves a botched spin-off execution, leading to higher-than-expected separation costs, operational disruptions, and a failure to realize strategic benefits. Concurrently, a downturn in the agricultural cycle could pressure volumes and pricing. This could trigger multiple compression towards the stock's historical trough valuations and a re-test of its 52-week low of $60.54. From the current price of ~$78.59, this scenario implies a potential downside of approximately -23%. Additional downside could materialize if the company misses forward EPS estimates of ~$5.29, given the high embedded expectations.